We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.26 | 0.87% | 30.09 | 30.01 | 30.25 | 30.23 | 30.03 | 30.16 | 2,162,815 | 21:42:26 |
From May 2019 to May 2024
By Cecilia Butini
Roche Holding AG said Thursday that sales in the period from January to September fell on year, but it backed its outlook for 2020.
Sales at the Swiss pharmaceutical major were 43.98 billion Swiss francs ($48.15 billion) for the period, down from CHF46.07 billion in the same period last year, the company said.
The diagnostics division boosted company sales, particularly in the third quarter, driven by PCR tests for Covid-19.
The company expects sales to grow in the low-to-mid-single digit range in 2020, it said, confirming its previous outlook.
Roche also said that it plans to further increase its dividend in 2020.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 15, 2020 01:56 ET (05:56 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
